A phase III trial of setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity
Phase of Trial: Phase III
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Rhythm
- 04 Nov 2019 According to an Rhythm Pharmaceuticals media release, Dr. Peter Kuhnen is the lead investigator for this trial.
- 04 Nov 2019 Results published in the Rhythm Pharmaceuticals Media Release.
- 04 Nov 2019 According to an Rhythm Pharmaceuticals media release, data from this study are being presented in late-breaking research forum during the 37th Annual Meeting of The Obesity Society at ObesityWeek 2019 held, November 3-7, 2019 in Las Vegas.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History